PenumbraPEN
Market Cap: $7.91B
About: Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
Employees: 4,200
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
31% more repeat investments, than reductions
Existing positions increased: 136 | Existing positions reduced: 104
11% more call options, than puts
Call options by funds: $82.5M | Put options by funds: $74.1M
4.41% more ownership
Funds ownership: 87.38% [Q1] → 91.79% (+4.41%) [Q2]
0% more funds holding
Funds holding: 339 [Q1] → 339 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 59
15% less capital invested
Capital invested by funds: $7.55B [Q1] → $6.39B (-$1.15B) [Q2]
67% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 1 (-2) [Q2]
Research analyst outlook
15 Wall Street Analysts provided 1 year price targets over the past 3 months
15 analyst ratings
Leerink Partners Mike Kratky 64% 1-year accuracy 7 / 11 met price target | 29%upside $263 | Outperform Initiated | 3 Sept 2024 |
BTIG Ryan Zimmerman 56% 1-year accuracy 19 / 34 met price target | 10%upside $224 | Buy Maintained | 28 Aug 2024 |
Citigroup Joanne Wuensch 66% 1-year accuracy 25 / 38 met price target | 2%downside $200 | Neutral Maintained | 22 Aug 2024 |
BTIG Ryan Zimmerman 56% 1-year accuracy 19 / 34 met price target | 8%downside $187 | Buy Maintained | 31 Jul 2024 |
Baird David Rescott 43% 1-year accuracy 6 / 14 met price target | 12%downside $180 | Outperform Maintained | 31 Jul 2024 |
Financial journalist opinion
Based on 6 articles about PEN published over the past 30 days